Related Experiment Video
Updated: Nov 18, 2025
18:30
Rat Mesentery Angiogenesis Assay
Published on: June 18, 2011
14.1K
Endoglin Expression and Microvessel Density as Prognostic Factors in Pediatric Rhabdomyosarcoma
Joanna Radzikowska1, Antoni Krzeski1, Anna M Czarnecka2,3
1Department of Otorhinolaryngology, Faculty of Dental Medicine, Medical University of Warsaw, 19/25 Stepinska St., 00-739 Warsaw, Poland.
Journal of Clinical Medicine
|February 4, 2021
Summary
Microvessel density (MVD) using CD105 is a significant indicator in pediatric rhabdomyosarcoma (RMS). Higher MVD/CD105 levels correlate with increased risk of death in children with RMS.
Area of Science:
- Oncology
- Pathology
- Pediatric Research
Background:
- Rhabdomyosarcoma (RMS) is a pediatric soft tissue sarcoma.
- Understanding angiogenesis markers is crucial for RMS prognosis.
- Microvessel density (MVD) is a key indicator of tumor vascularity.
Purpose of the Study:
- To analyze microvessel density (MVD) in pediatric rhabdomyosarcoma (RMS).
- To evaluate the prognostic role of angiogenesis markers (CD31, CD34, CD105) in RMS.
- To determine the relationship between MVD and clinical prognostic parameters in RMS.
Main Methods:
- Analysis of CD31, CD34, and CD105 expression in tumor tissues from 49 pediatric RMS patients.
- Calculation of microvessel density (MVD) based on marker expression.
- Correlation of MVD with clinical prognostic parameters.
Main Results:
- CD31, CD34, and CD105 were expressed in all RMS cases.
- MVD/CD105 was significantly higher in RMS patients compared to controls.
- Higher MVD/CD105 was observed in alveolar RMS and metastatic disease, and associated with increased mortality risk (HR = 1.009).
Conclusions:
- CD105 is a relevant angiogenesis marker in pediatric RMS.
- MVD/CD105 serves as an independent risk factor for reduced overall survival in children with RMS.
- MVD assessment using CD105 aids in predicting outcomes for pediatric RMS patients.
